Feedback Mechanism of Focal Vascular Lesion Formation in Transgenic Apolipoprotein(a) Mice*
暂无分享,去创建一个
E. Rubin | A. Pearle | R. Lawn | D. Grainger | L. L. Kunz | J. Metcalfe | J. Reckless
[1] N. Morton,et al. Lp(a) lipoprotein as a risk factor for myocardial infarction. , 1986, JAMA.
[2] D. Bellinger,et al. Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a). , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.
[3] A. Stead,et al. Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. , 1995, Stroke.
[4] H. Moses,et al. Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium , 1988, The Journal of cell biology.
[5] D. Rifkin,et al. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture , 1989, The Journal of cell biology.
[6] D. Grainger,et al. A PIVOTAL ROLE FOR TGF‐β* IN ATHEROGENESIS? , 1995 .
[7] J. Douglas,et al. Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. , 1992, The American journal of cardiology.
[8] R. Lawn,et al. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice , 1994, Nature.
[9] P. Libby,et al. Regulation of smooth muscle cell scavenger receptor expression in vivo by atherogenic diets and in vitro by cytokines. , 1995, The Journal of clinical investigation.
[10] C. Rosen,et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[11] M. Debakey,et al. Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation. , 1989, Arteriosclerosis.
[12] J. Gamble,et al. Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-beta. , 1988, Science.
[13] G. Owens,et al. Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells , 1988, The Journal of cell biology.
[14] G. Proetzel,et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.
[15] M. Dietel,et al. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. , 1989, Arteriosclerosis.
[16] M. Sporn,et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[17] S. Hosoda,et al. Influence of plasma lipoprotein (a) levels on coronary vasomotor response to acetylcholine. , 1995, Journal of the American College of Cardiology.
[18] S. Schwartz,et al. Production of transforming growth factor beta 1 during repair of arterial injury. , 1991, The Journal of clinical investigation.
[19] G. Utermann,et al. The mysteries of lipoprotein(a). , 1989, Science.
[20] A. Grace,et al. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis , 1995, Nature Medicine.
[21] D. Rifkin,et al. Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration , 1991, The Journal of cell biology.
[22] J. Ordovás,et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. , 1994, JAMA.
[23] R. Ross. The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.
[24] B. Furie,et al. Antifibrinolytic activity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis , 1995, Nature Medicine.
[25] P L Weissberg,et al. Isolation of gene markers of differentiated and proliferating vascular smooth muscle cells. , 1993, Circulation research.
[26] P. Wilson,et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. , 1996, JAMA.
[27] D. Betteridge,et al. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. , 1994, The Journal of clinical investigation.
[28] R. Derynck,et al. Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[29] R. Hammer,et al. Atherogenesis in transgenic mice expressing human apolipoprotein(a) , 1992, Nature.
[30] C. Hamm,et al. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a) , 1995, Circulation.
[31] P. Weissberg,et al. Proliferation of human smooth muscle cells promoted by lipoprotein(a). , 1993, Science.
[32] D. Grainger,et al. Tamoxifen elevates transforming growth factor–β and suppresses diet–induced formation of lipid lesions in mouse aorta , 1995, Nature Medicine.
[33] A. von Eckardstein,et al. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. , 1996, The American journal of cardiology.
[34] D. Grainger,et al. Optimization of immunofluorescence methods by quantitative image analysis. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[35] G. McDonald,et al. The fine structure of human rectal epithelium in acute graft‐versus‐host disease , 1982, The American journal of surgical pathology.
[36] P. Weissberg,et al. Tamoxifen decreases the rate of proliferation of rat vascular smooth-muscle cells in culture by inducing production of transforming growth factor beta. , 1993, The Biochemical journal.
[37] P. Nestel,et al. Metabolism of Atherogenic Lipoproteins by Smooth Muscle Cells of Different Phenotype in Culture , 1985, Arteriosclerosis.
[38] A. M. Lefer,et al. Mechanism of the cardioprotective effect of transforming growth factor beta 1 in feline myocardial ischemia and reperfusion. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[39] E. Chen,et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen , 1987, Nature.
[40] B. Nordestgaard,et al. Specific accumulation of lipoprotein(a) in balloon-injured rabbit aorta in vivo. , 1996, Circulation research.
[41] R. Assoian,et al. Transforming growth factor-beta 1 inhibits scavenger receptor activity in THP-1 human macrophages. , 1991, The Journal of biological chemistry.
[42] S. Schwartz,et al. Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2aR). , 1991, Biochemical and biophysical research communications.
[43] R. Nachman. Review: Stratton Lecture. Thrombosis and atherogenesis: molecular connections. , 1992, Blood.